Arixtra safety update
This article was originally published in Pharmaceutical Approvals Monthly
FDA approves labeling revision for Organon/Sanofi-Synthelabo's deep vein thrombosis agent Arixtra (fondaparinux) Dec. 4, removing a caveat that improved efficacy seen versus Aventis' Lovenox (enoxaparin) may have been influenced by timing of the first dose and eliminating a statement that there was a higher bleeding rate with Arixtra. In the initial review, FDA felt that the rate of bleeding and venous thromboembolisms in clinicals might have been affected by deviance from the dosing schedule (Pharmaceutical Approvals Monthly, May 1, 2002, p. 33). Other labeling revisions include the addition of VTE relative risk reduction figures. Revised labeling could allow the companies to boost sales; Arixtra's launch has been slower than expecte
You may also be interested in...
The pandemic has exacerbated the problems of the Turkish medical device industry, which was already struggling for survival and growth in a hostile policy environment. Local blood bag manufacturer Kansuk Laboratory talked to Medtech Insight about the difficulties it faces.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Medicines for Ireland has released a report focusing on the direct impact of Brexit and COVID-19 on the medicines supply chain. The association has called for long-term plans and solutions instead of temporary fixes for issues related to delays in the import and export of medicines.